Why Is NOVAVAX INC (NVAX) Stock Down Today?

Novavax Inc (NVAX) shares fell 12.22% to $8.76, marking a significant decline driven by continued underperformance relative to competitors and deteriorating fundamental metrics. The stock printed 35 fresh 52-week lows on November 12, 2026, capping a session that saw the price slide from an opening level of $9.98 to a session low of $8.75.

What Happened

The primary driver for the move appears to be a combination of relative weakness against peers and recent analyst activity. Novavax management announced it will participate in the Jefferies London Healthcare Conference, a standard corporate event that did not halt the selling pressure. Concurrently, B. Riley Securities reiterated a Buy rating on the stock but lowered its price target to $16. While the rating remained positive, the reduction in the target price alongside broader market underperformance contributed to the downward momentum. The company recently reported third-quarter 2026 financial results, which highlighted operational challenges.

What The Data Shows

Fundamental data underscores the pressure on the equity. The company has a market capitalization of $1.7 billion and remains unprofitable, with a trailing twelve-month EPS of -0.47. Revenue has declined 61.3% over the same period, and the net margin stands at -18.6%. The stock carries a high beta of 2.72, indicating elevated volatility relative to the broader market. Intraday, the stock opened at $9.98 and hit a high of $10.03 at 7:45 AM ET before drifting lower to close near the session low. Volume reached 6.3 million shares, which is 1.1 times the three-month daily average. The 52-week range spans from $6.20 to $13.38. Over the last eight sessions, the stock had gained 4.7%, moving from $9.53 to $9.98, before this sharp reversal. Social chatter remains minimal, with only one post recorded in the last seven days.

What To Watch

Investors should monitor the company's upcoming participation in the Jefferies London Healthcare Conference for any new operational updates. Additionally, the continued trend of analysts revising financial forecasts and adjusting price targets will be key indicators of how the market digests Novavax's recent financial performance and revenue trajectory.